X

Zandu Realty Ltd. - (Amalgamated) Stock Analysis

Small Cap
Evaluated by 459 users | BSE: 506720 | NSE: ZANDUREALT |
Pharmaceuticals & Drugs
Zandu Pharmaceutical works name was changed to Zandu Realty from March 10, 2010. At present, the company is a multi-product entity, comprising a group of companies. Zandu projects a sale of nearly Rs. 2,000/- Million by 2000 A.D.It was listed in 1919; is engaged in offering ayurvedic...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17
Return on Capital Employed 22.01%27.69%5.56%0.62%-29.89%0.67%18.66%29.58%4.05%3.05%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 13687.3007002986.98.75.1
Y-o-Y Gr. Rt.--35.9%-100%NANA-100%NA199.3%-90%-40.8%
Adjusted EPS (Rs.) 196.39171.0416.3511.34-871.5516.72476.59797.0687.4164.21
Y-o-Y Gr. Rt.--12.9%-90.4%-30.6%-7785.6%NA2750.4%67.2%-89%-26.5%
Book Value per Share (Rs.) 962.87285.4302.64313.98886.98903.71,380.282,177.342,264.762,328.96
Adjusted Net Profit 15.813.81.30.9-70.31.438.464.37.15.2
Net Op. Cash Flow (Rs. Cr.) 22.813.50-1.472.2-565.67-36
Debt to Cash Flow from Ops 0.010000004.9901.92
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Zandu Realty Ltd. - (Amalgamated) should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales -30.5%-40.7%-43.9%-40.8%
Adjusted EPS -11.7%NA-48.7%-26.5%
Book Value per Share 10.321.319.12.8
Share Price -9.3% -8.9% -13.5% -54.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17
Return on Equity (%) 21.6827.45.560.62-29.890.6718.5531.373.592.63
Operating Profit Margin (%) 17.0720.7600-102.05077.32-3.48-39.22-72.6
Net Profit Margin (%) 11.6215.800-100.40132.3473.9681.32100.98
Debt to Equity 00000000.200.06
Working Capital Days 8673001,25501,5744923,1822,998
Cash Conversion Cycle 940094101,369281892969
Entity Percentage Holding
Promoters 35.51%
Institutions 0.13%
Non-Institutions 64.36%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Zandu Realty-(Amalga's performance infers:

Zandu Realty-(Amalga earnings have grown by 0%, whereas share price has depreciated -8.9% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Zandu Realty-(Amalga share prices over the last 10 years. Here is what we found out:

Zandu Realty-(Amalga share price has depreciated -12.5% annually over the past ten years.

Zandu Pharmaceutical works name was changed to Zandu Realty from March 10, 2010. At present, the company is a multi-product entity, comprising a group of companies. Zandu projects a sale of nearly Rs. 2,000/- Million by 2000 A.D.

It was listed in 1919; is engaged in offering ayurvedic healthcare medicines.

Zandu manufactures a wide range of ayurvedic medicine specialised in area of rheumatology, gynaecology and CNS (Central nervous system).

Using 200 medicinal plants and their

Zandu Pharmaceutical works name was changed to Zandu Realty from March 10, 2010. At present, the company is a multi-product entity, comprising a group of companies. Zandu projects a sale of nearly Rs. 2,000/- Million by 2000 A.D.

It was listed in 1919; is engaged in offering ayurvedic healthcare medicines.

Zandu manufactures a wide range of ayurvedic medicine specialised in area of rheumatology, gynaecology and CNS (Central nervous system).

Using 200 medicinal plants and their extracts it manufactures 300 healthcare products. The company markets its products under the brand name Zandu.

The company exports herbal health care products to U.S.A, Europe and Asian countries.

The chemical division is located at Ankleshwar that manufactures bulk drugs and intermediates. The cosmetics division manufactures wide range of skin care products such as lotion, soaps, shampoo, creams, etc. It markets the cosmetic products under name Z-naree.

It manufactures products such as zandu balm, brento, kesari-jivan, zandu honey, triphala churna, sudarshan, rhumasyl oil, gulbahar, chandra prabhavati, etc.

ZPWL has formed joint venture with Gujarat Agro Industries Corporation to manufacture glycyrrhiza extract from a vegetable plant-extraction project.

In the year 1989 Leopard Investments Private Limited has become the subsidiary of ZPWL.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323
Research Analyst - INH000000719

Callback